↓ Skip to main content

Cochrane Database of Systematic Reviews

Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension

Overview of attention for article published in Cochrane database of systematic reviews, October 2008
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
12 news outlets
twitter
11 tweeters
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
127 Dimensions

Readers on

mendeley
229 Mendeley
citeulike
1 CiteULike
Title
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension
Published in
Cochrane database of systematic reviews, October 2008
DOI 10.1002/14651858.cd003823.pub2
Pubmed ID
Authors

Balraj S Heran, Michelle MY Wong, Inderjit K Heran, James M Wright

Abstract

ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE). To quantify the dose-related systolic and/or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension. We searched CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to February 2007), EMBASE (1988 to February 2007) and reference lists of articles. Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an ACE inhibitor compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension. Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials. Ninety two trials evaluated the dose-related trough BP lowering efficacy of 14 different ACE inhibitors in 12 954 participants with a baseline BP of 157/101 mm Hg. The data do not suggest that any one ACE inhibitor is better or worse at lowering BP. A dose of 1/8 or 1/4 of the manufacturer's maximum recommended daily dose (Max) achieved a BP lowering effect that was 60 to 70% of the BP lowering effect of Max. A dose of 1/2 Max achieved a BP lowering effect that was 90% of Max. ACE inhibitor doses above Max did not significantly lower BP more than Max. Combining the effects of 1/2 Max and higher doses gives an estimate of the average trough BP lowering efficacy for ACE inhibitors as a class of drugs of -8 mm Hg for SBP and -5 mm Hg for DBP. ACE inhibitors reduced BP measured 1 to 12 hours after the dose by about 11/6 mm Hg. There are no clinically meaningful BP lowering differences between different ACE inhibitors. The BP lowering effect of ACE inhibitors is modest; the magnitude of trough BP lowering at one-half the manufacturers' maximum recommended dose and above is -8/-5 mm Hg. Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. The review did not provide a good estimate of the incidence of harms associated with ACE inhibitors because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 229 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
South Africa 2 <1%
United Kingdom 1 <1%
Unknown 226 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 41 18%
Student > Master 39 17%
Student > Ph. D. Student 25 11%
Researcher 21 9%
Student > Doctoral Student 14 6%
Other 39 17%
Unknown 50 22%
Readers by discipline Count As %
Medicine and Dentistry 86 38%
Pharmacology, Toxicology and Pharmaceutical Science 20 9%
Nursing and Health Professions 17 7%
Agricultural and Biological Sciences 16 7%
Biochemistry, Genetics and Molecular Biology 8 3%
Other 21 9%
Unknown 61 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 101. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2022.
All research outputs
#330,643
of 21,963,432 outputs
Outputs from Cochrane database of systematic reviews
#602
of 12,153 outputs
Outputs of similar age
#4,545
of 324,743 outputs
Outputs of similar age from Cochrane database of systematic reviews
#16
of 244 outputs
Altmetric has tracked 21,963,432 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,153 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,743 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 244 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.